Dr. Maralani describes her experience with OAB treatment InterStim

Data from phase 2 of the SANS-UUI trial are expected to support an application to the FDA for approval of the device in patients with urge urinary incontinence.

“We know that erectile dysfunction is really an important issue that can be a harbinger for other underlying cardiovascular or neurological health issues,” says Michael Lutz, MD.

"We believe the collective findings are unique in urogynecology and offer strong evidence that first-line incontinence treatment is effective, and women can access it using the Leva System,” says Evelyn Hall, MD.

“I think it's really important to understand the role of prevention and early detection,” says Michael Lutz, MD.

“We think artificial intelligence has a wide variety of applications that will benefit urologists both in and out of training,” says Mubashir S. Billah, MD.

The decision is supported by findings from the phase 3 EMPOWUR trial and the phase 3 EMPOWUR extension study.